AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Financial Results | TNF Pharmaceuticals 2024 Full Year Net Loss USD 23.36 Million
ByAinvest
Saturday, Apr 12, 2025 6:00 am ET1min read
TNF Pharmaceuticals(TNFA) posted the Q4 of its 2024 financial results on 4/11/2025, reporting net loss of USD 23.36 million for the year, expanding 483.99% from USD -4.00 million year over year. The EPS is USD -11.15 for the year, compare with USD -5.33 last period.
[Detailed Data]
| Million USD | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Total Operating Expenses | 2.04 | 1.66 | 3.35 | 2.77 |
| Operating Income | -2.04 | -1.66 | -3.35 | -2.77 |
| Net Income | -2.06 | -1.93 | -9.57 | -9.80 |
| Net Income Attributable to Common Shareholders | -3.14 | -2.68 | -10.34 | -11.00 |
| EPS(USD) | -0.9323 | -1.11 | -4.54 | -5.14 |
[Company Profile]
TNF Pharmaceuticals, Inc., incorporated under the laws of the State of New Jersey on March 9, 1989 under the name A.R.C. Enterprises, Inc. On July 22, 2024, the Company changed its incorporation to the State of Delaware. The company is a clinical stage pharmaceutical company committed to extending healthy lifespan. TNF is focused on developing and commercializing two therapeutic platforms based on well-defined therapeutic targets, Isomyosamine and Supera-CBD.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet